Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial

Journal of the American Academy of Dermatology

Volumn 51, Issue 4, 2004, Pages 534-542

  Gottlieb, Alice B ^a,b   Evans, Robert ^a   Li, Shu ^a   Dooley, Lisa T ^a   Guzzo, Cynthia A ^a   Baker, Daniel ^a   Bala, Mohan ^a   Marano, Colleen W ^a   Menter, Alan ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY   (United States)

Author keywords

ANAs; antinuclear antibodies; Dermatology Life Quality Index; DLQI; double stranded DNA; dsDNA; PASI; PGA; Physician Global Assessment; Psoriasis Area and Severity Index; TNF; tumor necrosis factor

Indexed keywords

INFLIXIMAB; PLACEBO;

ADULT; ARTICLE; BACKACHE; CHILL; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIVERTICULITIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DYSPNEA; FEMALE; FLUSHING; HEADACHE; HUMAN; INJECTION SITE; LUPUS ERYTHEMATOSUS; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PSORIASIS VULGARIS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEPSIS; SIDE EFFECT; SKIN INFILTRATE; SQUAMOUS CELL CARCINOMA; TASTE DISORDER; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CHILLS; DOUBLE-BLIND METHOD; FEMALE; FLUSHING; HEADACHE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4644327125     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.02.021     Document Type: Article

References (44)

1. Rapp S.R., Feldman S.R., Exum M.L., Fleischer A.B., Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 41:1999;401-407
2. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 137:2001;280-284
3. Ellis C.N., Fradin M.S., Messana J.M., Brown M.D., Siegel M.T., Hartley A.H., et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 324:1991;277-284
4. Boffa M.J., Chalmers R.J.G. Methotrexate for psoriasis. Clin Exp Dermatol. 21:1996;399-408
5. Cather J., Menter A. Novel therapies for psoriasis. Am J Clin Dermatol. 3:2002;159-173
6. Gottlieb A.B. Clinical research helps elucidate the role of tumor necrosis factor-α in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus. 12:2003;190-194
7. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 46:2002;1-23
8. Oh C.J., Das K.M., Gottlieb A.B. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 42:2000;829-830
9. Gottlieb A.B., Masud S., Ramamurthi R., Abdulghani A., Romano P., Chaudhari U., et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 48:2003;68-75
10. Girolomoni G., Pastore S., Albanesi C., Cavani A. Targeting tumor necrosis factor-α as a potential therapy in inflammatory skin diseases. Curr Opin Investig Drugs. 3:2002;1590-1595
11. Asadullah K., Volk H.D., Sterry W. Novel immunotherapies for psoriasis. Trends Immunol. 23:2002;47-53
12. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet. 357:2001;1842-1847
13. Gottlieb A.B., Chaudhari U., Mulcahy L.D., Li S., Dooley L.T., Baker D.G. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 48:2003;829-835
14. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 356:2000;385-390
15. Lebwohl M. Psoriasis. Lancet. 361:2003;1197-1204
16. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine. 7:1995;251-259
17. Fredriksson T., Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 157:1978;238-244
18. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 19:1994;210-216
19. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., MacFarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor [alpha] monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1998;1552-1563
20. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 117:1999;761-769
21. Wagner C.L., Schantz A., Barnathan E., Olson A., Mascelli M.A., Ford J., et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol. 112:2003;37-53
22. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol. 139:1998;88-95
23. Ellis C.N., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 345:2001;248-255
24. Ellis C.N., Mordin M.M., Adler E.Y. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 4:2003;131-139
25. Finlay A.Y., Salek M.S., Haney J., for The Alefacept Clinical Study Group. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology. 206:2003;307-315
26. Kurwa H.A., Finlay A.Y. Dermatology in-patient management greatly improves life quality. Br J Dermatol. 133:1995;575-578
27. Vensel E., Hilley T., Trent J., Taylor J.R., Kirsner R.S., Kerdel F.A., et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol. 43:2000;858-860
28. Remicade [package insert]. 2003;Centocor Inc, Malvern, PA
29. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 348:2003;601-608
30. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol In press.
31. Hanauer S.B. Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 348:2003;2155-2156
32. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 359:2002;1541-1549
33. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 24:2002;1720-1740
34. Pendley C., Schantz A., Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther. 5:2003;172-179
35. Embrel [package insert]. 2003;Immunex Corp, Thousand Oaks (CA)
36. Humira [package insert]. 2003;Abbott Laboratories, North Chicago, IL
37. Charles P.J., Smeenk R.J.T., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43:2000;2383-2390
38. Kavanaugh A., Keenan G., DeWoody K., Marsters P., Hendricks D., Clark J., et al. Long-term follow-up of patients treated with Remicade (infliximab) in clinical trials. Arthritis Rheum. 44:(Suppl):2001;S81
39. Shakoor N., Michalska M., Harris C.A., Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 359:2002;579-580
40. Debandt M., Vittecoq O., Descamps V., Le Loët X., Meyer O. Anti-TNF-a-induced systemic lupus syndrome. Clin Rheumatol. 22:2003;56-61
41. Nickoloff B.J., Karabin G.D., Barker J.N.W.N., Griffiths C.E.M., Sarma V., Mitra R.S., et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 138:1991;129-140
42. Ettehadi P., Greaves M.W., Wallach D., Aderka D., Camp R.D.R. Elevated tumor necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol. 96:1994;146-151
43. Groves R.W., Allen M.H., Ross E.L., Barker J.N.W.N., MacDonald D.M. Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol. 132:1995;345-352
44. Skobe M., Detmar M. Structure, function, and molecular control of the skin lymphatic system. J Invest Dermatol. 5:2000;14-19